Elotuzumab
- Generic Name
- Elotuzumab
- Brand Names
- Empliciti
- Drug Type
- Biotech
- CAS Number
- 915296-00-3
- Unique Ingredient Identifier
- 1351PE5UGS
- Background
Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb.
- Indication
Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.
- Associated Conditions
- Refractory Multiple Myeloma
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Celgene
- Target Recruit Count
- 381
- Registration Number
- NCT03651128
- Locations
- 🇺🇸
Local Institution - 145, Los Angeles, California, United States
🇺🇸Local Institution - 122, Los Angeles, California, United States
🇺🇸Local Institution - 131, Atlanta, Georgia, United States
Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2023-03-29
- Target Recruit Count
- 18
- Registration Number
- NCT03411031
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Registration Number
- NCT03393273
- Locations
- 🇫🇷
Hématologie et thérapie cellulaire, Hôpital Saint Antoine, Paris, France
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2017-12-04
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 15
- Registration Number
- NCT03361306
- Locations
- 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT03227432
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- University of Arkansas
- Registration Number
- NCT03168100
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines
- Conditions
- Multiple Myeloma in Relapse
- Interventions
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Raija Silvennoinen
- Target Recruit Count
- 15
- Registration Number
- NCT03155100
- Locations
- 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland
🇫🇮Central Finland Central Hospital, Jyväskylä, Finland
🇫🇮Kymenlaakso Central Hospital, Kotka, Finland
Combination Study for High Risk Multiple Myeloma Patients
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2017-04-07
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 13
- Registration Number
- NCT03104270
- Locations
- 🇺🇸
Robert A. Moss, MD, FACP, Inc, Fountain Valley, California, United States
🇺🇸Pacific Cancer Care, Monterey, California, United States
🇺🇸California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
- Conditions
- Multiple Myeloma in Relapse
- Interventions
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 25
- Registration Number
- NCT03030261
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Colorado Blood Cancer Institute (Sarah Cannon), Denver, Colorado, United States
🇨🇦University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2018-05-23
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 6
- Registration Number
- NCT03023527
- Locations
- 🇪🇸
Hospital Clinic, Barcelona, Spain
🇪🇸ICO Badalona, Badalona, Spain
🇪🇸Hospital Ramón y Cajal, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.